In silico investigation of cytochrome bc1 molecular inhibition mechanism against Trypanosoma cruzi

Chagas' disease is a neglected tropical disease caused by the kinetoplastid protozoan Trypanosoma cruzi. The only therapies are the nitroheterocyclic chemicals nifurtimox and benznidazole that cause various adverse effects. The need to create safe and effective medications to improve medical care remains critical. The lack of verified T. cruzi therapeutic targets hinders medication research for Chagas' disease. In this respect, cytochrome bc1 has been identified as a promising therapeutic target candidate for antibacterial medicines of medical and agricultural interest. Cytochrome bc1 belongs to the mitochondrial electron transport chain and transfers electrons from ubiquinol to cytochrome c1 by the action of two catalytic sites named Qi and Qo. The two binding sites are highly selective, and specific inhibitors exist for each site. Recent studies identified the Qi site of the cytochrome bc1 as a promising drug target against T. cruzi. However, a lack of knowledge of the drug mechanism of action unfortunately hinders the development of new therapies. In this context, knowing the cause of binding site selectivity and the mechanism of action of inhibitors and substrates is crucial for drug discovery and optimization processes. In this paper, we provide a detailed computational investigation of the Qi site of T. cruzi cytochrome b to shed light on the molecular mechanism of action of known inhibitors and substrates. Our study emphasizes the action of inhibitors at the Qi site on a highly unstructured portion of cytochrome b that could be related to the biological function of the electron transport chain complex. Author summaryChagas' disease is caused by the parasite Trypanosoma cruzi, which is prevalent in low-income African, Asian, and American countries and spread through the rest of the world through migrations infecting about 8 million people and causing 10 000 deaths per year. Currently, the only drugs approved for treating Chagas' disease have various side effects. Identifying proteins of the parasite that can limit its activity can help the development of new and more effective drugs. In this context, the cytochrome bc1 of Trypanosoma cruzi has been identified as a promising drug target. However, it is unclear how certain drugs affect cytochrome bc1 biological activity. Molecular dynamics simulations have been used to analyze the impact of specific small molecules on protein conformational changes that may be related to cytochrome bc1's biological function. This manuscript presents a computational approach that could identify small-molecule lead compounds and distinguish between true and false cytochrome b inhibitors.